Adverse events (grade ≥3) in overall immunotherapy and subgroups of advanced NSCLC patients.

Note: mAbs, monoclonal antibodies; OR, odds ratio. CI, confidence interval. No treatment-related adverse events (grade ≥3) were observed in trials by Neninger Vinageras et al. [21] and Wu et al. [30]; serious adverse events occurred but significantly less frequently in immunotherapy groups than in control groups and no detailed data were presented in studies by Lissoni et al. [16] and Butts et al. [22].